cagrisema semaglutide cagrilintide phase 3 results 2024 2025 Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has well-established weight-loss benefits. Cagrilintide, a long-acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit cagrisema semaglutide cagrilintide phase 3

If you have type 2 diabetes and have been diagnosed with heart disease or chronic kidney disease, this update is worth raising with your doctor or endocrinologist at your next appointment

ACHIEVE-1 (fase 3, diabetes type 2 eerste succesvolle fase 3 voor een niet-peptide GLP-1) 559 volwassenen met vroege diabetes type 2, 40 weken behandeling

Updated 2022

By teaching young adults to make healthcare a priorityeven though they may feel invincibleparents can help set them up for future success

Thyroid cancer Do not take semaglutide if you or any of your family have ever had medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)